대한뉴팜

Wonsuk Lee was inaugurated as CEO and President of Daehan Nupharm on January 2. Born in 1977, he joined the company in 2004, progressing through roles in the overseas business team, finance team, and management team, and most recently served as Vice President of the Management Headquarters. At the inauguration ceremony held together with the 2023 kick-off meeting, he was awarded the Long-term Service Award and the Daehan Nupharm Person of the Year Award. In his inaugural speech, he outlined future management policies centered on the keywords “listening,” “action,” and “responsibility.” Daehan Nupharm is a pharmaceutical and veterinary medicine manufacturer and distributor focused on developing biopharmaceuticals and improved new drugs. The company plans to launch a variety of pharmaceuticals and health supplements, including ‘Zero-Be’ tablets that improve dosing convenience and ‘Cambel Double’ tablets, which are twice the dosage of the 'Cambel' herbal formula. The company has also been preparing for pet product development for several years and aims to release eight items this year. It is strengthening R&D for new drug development, having completed the Industry-Academia-Research Center in the Second Pangyo Techno Valley in 2021. The center is designed to improve work efficiency and welfare through the keywords “research and development” and “communication.” In his speech, Lee emphasized creating synergies between the human pharmaceuticals, veterinary medicines, and health supplements divisions by newly establishing a Future Business Division and strengthening pipelines across divisions. He expressed his commitment to building a workplace where employees are proud to belong to Daehan Nupharm and rewarded for their achievements as the company grows into a global pharmaceutical and bio company.

Daehan Nupharm reported third-quarter sales of approximately 147.9 billion KRW, an 18% increase compared to the same period last year, with an operating profit of 21.2 billion KRW (operating margin of 14.3%). Additionally, the company posted a net profit of 20.8 billion KRW, up 48% year-on-year, boosted by an 8.9 billion KRW income from winning a lawsuit. The company continues to grow by focusing on improved new drugs, biopharmaceutical development, and veterinary medicines. They plan to launch various pharmaceuticals, health supplements, and animal drugs from the fourth quarter through early next year. First, the recent launch of the DPP-4 inhibitor for type 2 diabetes patients, including the single-agent 'Teneltin tablet' and the combination drug 'Tenelpomin extended-release tablet', provides new momentum, offering benefits like no risk of hypoglycemia or weight gain and suitability irrespective of kidney function. Second, enhanced-compliance drugs 'Zero-Be tablet' and 'Cambel Double tablet', which doubles the dosage of the 'Cambel tablet' herbal formula, are expected to be launched in February 2023, improving stability and dosing convenience. Third, the hospital-exclusive health supplement brand 'Dr. DiNU' will launch in November with four new products including high-purity phosphatidylcholine, Super Arginine 5000, Glutamine 6000, and Immune Alpha Capsule, expanding the health supplement sales channel. Fourth, Daehan Nupharm is expanding its pet products with the upcoming Q4 launch of 'RS-Pro', a natural ingredient-based supplement improving skin and hair conditions, showing effects on promoting hair growth and alleviating skin issues without steroids. These initiatives underscore Daehan Nupharm's sustained growth strategy through diverse product innovation across pharmaceuticals, supplements, and veterinary care.

Daehan Nupharm achieved sustained growth with second-quarter sales of 96.2 billion KRW, marking a 15% increase year-over-year.Operating profit reached 12.7 billion KRW, and net profit climbed to 14.9 billion KRW, boosted by an 8.9 billion KRW gain related to a lawsuit victory.The operating margin was 13%. The company plans to continue expanding with new product launches across pharmaceutical, health supplement, and veterinary medicine divisions. Notably, the pet product brand 'DiAnge' is set to aggressively expand sales activities following its launch in May.New products for animal health and stress relief are also planned for release in the second half of the year.

Daehan Nupharm launched the pet hospital-exclusive brand 'DiAnge', releasing its first product, a multi-strain probiotic called 'UD Pro'. The brand name combines Daehan Nupharm's initial ‘D’ with the French word 'Ange' meaning ‘angel,’ symbolizing products developed and supplied for “pets, who are angels to their owners,” and for veterinarians, the “guardian angels” of these pets. The first product, UD Pro, contains five probiotic strains including Lactobacillus crispatus and demonstrated kidney disease improvement effects in an eight-week feeding trial with pets suffering from renal disease. Blood serum chemistry tests showed decreases in BUN, creatinine, and B/C ratio, along with overall improvements in fur condition and behavior. UD Pro’s probiotics,ed by the Ministry of Agriculture, Food and Rural Affairs-certified institution for acid resistance, bile tolerance, and intestinal adhesion capability, are manufactured with a special method maintaining long-term stability in liquid refrigerated form. The liquid product is conveniently administered by adding 3–8s to food or treats, enhancing ease of administration compared to powder or capsule forms. Daehan Nupharm is also strengthening veterinary pharmaceutical pipelines, planning sequential launches within the year of antiemetics, heartworm preventatives, antifungals, NSAID drugs for pets, and pancreatic function enhancers. This evidences Daehan Nupharm’s holistic growth in pet health through specialized nutrition and pharmaceutical solutions.

Daehan Nupharm achieved sales of 45.6 billion KRW in the first quarter of 2022, representing a 16% increase compared to the same period of the previous year. Operating profit rose 7.6% to 7.1 billion KRW, and net profit reached 11.6 billion KRW, a 191% increase year-on-year, driven by a favorable final ruling in a lawsuit resulting in the reversal of approximately 9 billion KRW in litigation reserves. The human pharmaceuticals division showed strong growth due to increased sales of antibiotics and respiratory disease treatments amid the spread of the Omicron variant, as well as growth in the company's core injectable products. Sales of obesity-related products are rising with the approach of the summer season, supporting expectations of continued growth in the second half. The animal health division launched the antibiotic tulathromycin and plans to introduce hormone products for pigs, stress relief agents 'Pamdi Zero', and aquatic stress relievers 'Aqua Luthione' in the second half. The company is actively advancing both industrial and companion animal businesses. Overseas exports are growing with increasing demand for the company's freeze-dried injectable product 'Liporase' beyond Southeast Asia into Latin America and the Middle East. Registrations in Iran and Peru have been recently completed, with the first shipments in March encouraging export growth. Daehan Nupharm reports balanced growth across all divisions, expecting further expansion through rising overseas demand for injectable products and global market development.

Daehan Nupharm unveiled its new Corporate Identity (CI). The new symbol represents the company’s initial ‘D’ as a cell, the basic unit of life, extending outward. The English name was changed from New Pharm to Nupharm, creating a single word without changing pronunciation. Founded in 1984, Daehan Nupharm started with animal feed additives and has grown into a mid-sized pharmaceutical and bio company listed on KOSDAQ, operating in human pharmaceuticals, veterinary medicines, biopharmaceuticals, medical devices, and health supplements. The company has maintained an average annual growth rate of 15% over the past decade, reaching sales of 166.5 billion KRW in 2021 and consistently exceeding 10 billion KRW in exports since receiving the ‘Ten Million Dollar Export Tower’ award in 2015. To enhance research capabilities and improve work environments, Daehan Nupharm completed its Industry-Academia-Research Center in the 2nd Pangyo Techno Valley and relocated its Hwaseong Central Research Institute and Osong Bio Research Institute to Pangyo, fostering synergy across divisions. The company is also constructing a new research building at its headquarters in the Hyangnam Pharmaceutical Industrial Complex this year. Alongside the new CI, Daehan Nupharm launched the campaign, sharing a vision to grow together with employees and become a global pharmaceutical and bio company that spreads warmth. The focus is on discovering future growth engines and enhancing core competencies in each division to ensure sustainable growth.

Daehan New Pharm’s health functional food brand, 'DiNU', has officially launched its online store. The newly opened DiNU online store offers new products like ‘DiNU Paraotics’ and ‘DiNU Polis,’ along with renewed versions of ‘Ascorbic Acid’ and ‘MSM,’ which have been professionally distributed by Daehan New Pharm, now directly available to consumers. To celebrate the official store opening, DiNU is running events with various benefits and plans to continuously provide reliable health information. The online store supports convenient access to health information and product purchases not only on PC but also in mobile environments. Additionally, subscription services allow consumers to receive health supplements that require long-term consistent intake via automatic payment and delivery without needing to buy every time. Daehan New Pharm plans to continue developing and launching high-quality, high-functionality products under the slogan, "Redefining nutrition and focusing on function." As part of the opening celebration, members who purchase ‘DiNU Polis’ throughout February will receive an additional same product for free. There is also an ongoing event where participants writing reviews have a chance to win Starbucks coupons. New members are offered various other benefits as well.

The health functional food brand 'DiNU: define nutrition' has launched ‘Paraotics.’ Paraotics is the first product in Korea to apply a dual-capsule formulation using the ‘capsule-in-capsule’ technology. The capsule containing probiotics is coated with an enteric coating and then enclosed within another capsule containing natural prebiotic ingredients. Unlike conventional probiotic products that have only a single coating, this dual-capsule design enhances the delivery and survival rate of probiotics in the intestines. The inner capsule contains four patented strains of probiotics from Danisco (La-14, Lpc-37, Lp-115, BI-04) and Lactobacillus rhamnosus GG, known for its high intestinal adherence, along with prebiotics, probiotic cultures (postbiotics), and probiotic cell lysates (parabiotics). All probiotic strains included have been clinically proven for efficacy, and the formulation includes an effective number of viable bacteria. The outer capsule contains New Zealand golden kiwi powder, which is distinct from traditional purified prebiotics, as it is made by pulverizing whole natural kiwis, allowing intake of dietary fiber and valuable vitamins and minerals. Clinical studies have confirmed that consuming freeze-dried kiwi powder promotes the growth of beneficial gut bacteria. The dual-capsule technology used in DiNU Paraotics is designed to dissolve sequentially in the stomach and intestines, maximizing the effectiveness of probiotics by delivering active ingredients to the appropriate site. This formulation technology is a first in health supplements, and the goal is to apply dual-release technology to functional ingredients in the future to enhance their absorption and efficacy. Taking two capsules daily provides 5 billion probiotics. The specially designed container allows easy storage at room temperature. DiNU Paraotics, along with DiNU Polis and other DiNU health supplements, are available for purchase on the Naver Smart Store 'DiNU store'. According to the Korea Health Supplements Association report on the functional food market and consumer survey, the health supplement market size reached approximately 4.98 trillion KRW last year, growing 6.6% from 2019. The probiotic market, in particular, expanded sharply by 19% to 885.6 billion KRW from 741.5 billion KRW the previous year. Industry experts expect the probiotic (functional probiotics) market to surpass 1 trillion KRW this year.

The company announced on the 11th that it achieved an accumulated operating profit of 22.1 billion won in the third quarter of 2021, marking a 12% increase year-on-year. Revenue grew 10% to 125.6 billion won, while net profit surged 123% to 14 billion won. All financial indicators showed improvement, with the current ratio—a measure of financial stability—rising by 42.8 percentage points to 179%, and the debt ratio decreasing by 36 percentage points to 96%. The pharmaceutical division contributed to sales growth through the launch of the new dyslipidemia combination drug “Newtozet” and the domestically exclusive carbohydrate absorption inhibitor “Migbos Film-Coated Tablet.” The company is also preparing to expand its diabetes medication portfolio next year by launching a generic version of a DPP-4 inhibitor, aiming to further boost revenue with new product introductions. In the health supplement division, the company is expanding its “DiNU (Define Nutrition)” brand, launched in the second half of this year. Starting with a dual-functional propolis combining Brazilian green propolis and vitamin C, it has released 3g of ascorbic acid from DSM (UK) and OptiMSM from the U.S. On the 11th, it will introduce “Pharaotics,” a probiotic product utilizing Korea’s first “cap-in-cap” technology. In the animal health division, the company plans to obtain product approval for “Trax Injection,” an antibacterial treatment for livestock respiratory diseases, with a commercial launch scheduled for this year. Since the patent expiration in the second half of 2019, domestic manufacturers have been able to produce and sell tulathromycin-based products. The tulathromycin market has grown from around 3 billion won before the patent expiry to approximately 9 billion won, and this product is expected to contribute to sales growth. The company continues to invest steadily in research and development across human pharmaceuticals, veterinary medicines, biopharmaceuticals, and health supplements, with new product launches progressing as planned. By achieving its fourth-quarter goals, the company aims to successfully close 2021 and move forward toward meeting its three-year targets through active recruitment in management, sales, R&D, and manufacturing.